Gong Jian, Zhang Haili, Xing Shushan, Li Chunde, Ma Zhenyu, Jia Ge, Hu Wanning
Department of Pediatric Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, China Beijing Neurosurgical Institute, Beijing, China.
Department of Oncology, Tangshan People's Hospital, Hebei United University, Hebei, China.
Cancer Biomark. 2014;14(4):241-51. doi: 10.3233/CBM-140397.
Adamantinomatous craniopharyngioma (ACP) is a benign but maldevelopmental tumor with a high recurrence rate.
Theaim of this study was to investigate the dysregulated biological molecules that play important roles in the recurrence of ACP.
We first performed microarray analysis on tumor samples from two pediatric patients with recurrent ACP and from two pediatric ACP patients without recurrence after a one-year follow-up. The expression of CXCL12 and CXCR4 in 45 specimens of pediatric ACP was further evaluated by immunohistochemistry. These results were correlated with the clinicopathological parameters and survival of the patients.
Four downregulated genes (APC, ITGA, MCAM, and TIMP4) and 16 upregulated genes (CST7, CTSK, CTSL1, CXCL12, CXCR4, FN1, FXYD5, ITGB3, MMP2, MMP3, MMP7, MMP9, NR4A3, PLAUR, TIMP2, and VEGFA) were found in the recurrent patients. CXCL12 and CXCR4 were highly expressed in 13 patients (28.9%) and 14 patients (31.1%), respectively. High levels of CXCL12 and CXCR4 expression were significantly associated with a poor recurrence-free survival and were the prognostic factors for ACP recurrence in pediatric patients.
High levels of CXCL12 and CXCR4 expression were associated with ACP recurrence. The role of CXCL12 and CXCR4 in the development of brain tumors requires further research.
造釉细胞瘤型颅咽管瘤（ACP）是一种良性但发育异常的肿瘤，复发率高。
本研究旨在探讨在ACP复发中起重要作用的失调生物分子。
我们首先对两名复发性儿科ACP患者和两名随访一年后未复发的儿科ACP患者的肿瘤样本进行了微阵列分析。通过免疫组织化学进一步评估45例儿科ACP标本中CXCL12和CXCR4的表达。这些结果与患者的临床病理参数和生存率相关。
在复发患者中发现了4个下调基因（APC、ITGA、MCAM和TIMP4）和16个上调基因（CST7、CTSK、CTSL1、CXCL12、CXCR4、FN1、FXYD5、ITGB3、MMP2、MMP3、MMP7、MMP9、NR4A3、PLAUR、TIMP2和VEGFA）。CXCL12和CXCR4分别在13例患者（28.9%）和14例患者（31.1%）中高表达。CXCL12和CXCR4的高表达水平与无复发生存期差显著相关，是儿科患者ACP复发的预后因素。
CXCL12和CXCR4的高表达与ACP复发相关。CXCL12和CXCR4在脑肿瘤发生中的作用需要进一步研究。
